FHTX
Foghorn Therapeutics Inc

598
Mkt Cap
$274.84M
Volume
362,364.00
52W High
$8.45
52W Low
$2.94
PE Ratio
-4.10
FHTX Fundamentals
Price
$4.59
Prev Close
$4.86
Open
$5.01
50D MA
$4.52
Beta
1.72
Avg. Volume
256,177.57
EPS (Annual)
-$1.58
P/B
-3.06
Rev/Employee
$201,803.57
Loading...
Loading...
News
all
press releases
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1d ago
News Placeholder
More News
News Placeholder
What is HC Wainwright's Estimate for FHTX FY2025 Earnings?
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a research note issued on...
MarketBeat·11d ago
News Placeholder
Wedbush Forecasts Higher Earnings for Foghorn Therapeutics
Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Investment analysts at Wedbush boosted their FY2025 earnings per share estimates for shares of Foghorn Therapeutics in a report released on...
MarketBeat·11d ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Now Covered by Analysts at Guggenheim
Guggenheim assumed coverage on shares of Foghorn Therapeutics in a report on Friday. They issued a "buy" rating and a $12.00 price target on the stock...
MarketBeat·12d ago
News Placeholder
Foghorn Therapeutics' (FHTX) Outperform Rating Reiterated at Wedbush
Wedbush restated an "outperform" rating and set a $10.00 price objective on shares of Foghorn Therapeutics in a report on Thursday...
MarketBeat·13d ago
News Placeholder
Foghorn Therapeutics (NASDAQ:FHTX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts...
MarketBeat·14d ago
News Placeholder
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +19.35% and +1.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·2mo ago
News Placeholder
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·3mo ago
News Placeholder
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies IQVIA and Flagship Pioneering Announce Strategic Collaboration to...
PR Newswire·3mo ago

Latest FHTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.